STOCK TITAN

Champions Oncology Announces Addition to Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

HACKENSACK, NJ / ACCESSWIRE / February 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR) a leading global oncology technology solutions provider transforming drug discovery through innovative pharmacology, biomarker, and data platforms, is pleased to announce the appointment of Rob Brainin to its Board of Directors. Rob is an experienced global life sciences and healthcare executive with more than 15 years of experience. His appointment will help guide the company's efforts to accelerate the development of its data platform for use in drug discovery. The Company also announced the resignation of current board member Abba Poliakoff.

Joel Ackerman, Chairman of the Board of Directors commented, "We are excited to have Rob join our Board of Directors. Rob has spent his career at the nexus of life science data and technology, and has leveraged his depth and breadth to become a leader in the use of genomic data to drive drug development. We expect his unique experience will be invaluable in helping us capitalize on our technology platform and evolve our strategy." Ackerman added, "We deeply appreciate Abba's many contributions to the development of Champions. He has been a valuable resource and advisor to the company during his many years of service."

Rob recently was the Chief Executive Officer of Genuity Science where he focused on ways to transform clinical and molecular data into real-life solutions, making complex multi-omic information actionable for global communities in their quest to improve healthcare. Before joining Genuity, Rob was Vice President and General Manager of Life Sciences and Applied Genomics at Illumina, having previously served as VP and Head of the Arrays Business. Rob has also held senior roles at Life Technologies, Invitrogen and Thermo Fisher. In all these roles, he led the expansion of the applications of technologies or genomic data to new fields to serve the needs of growing types of users. Rob holds an undergraduate degree in economics from Emory University and a law degree from Harvard Law School. He currently serves on the Board of Directors of The Children's Tumor Foundation.

Media Contact:

Rachel Bunting, MS, MBA
Sr. Director, Head of Marketing
Marketing@ChampionsOncology.com

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/630772/Champions-Oncology-Announces-Addition-to-Board-of-Directors

Champions Oncology, Inc.

NASDAQ:CSBR

CSBR Rankings

CSBR Latest News

CSBR Stock Data

66.61M
4.72M
25.56%
42.15%
0.43%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BALTIMORE

About CSBR

champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them